Cell Expansion Market Worth $39.7 Billion By 2027

The global cell expansion market size is expected to reach USD 39.7 billion by 2027 registering a CAGR of 9.4%, according to a new report by Grand View Research, Inc. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies. Therefore, significant developments in cord blood SCs expansion technologies are expected to boost market growth.

Companies have made heavy investments for the expansion of tissue-engineered products and the development of biologics. For instance, in March 2019, Merck KGaA invested USD 168 million for the expansion of its biologics manufacturing facility in Switzerland. Such initiatives are expected to boost the demand for solutions required for biologic development, thereby leading to market growth.

Bioreactors are fundamental tools in this market. Extensive research studies related to the applications of bioreactor engineering approaches have led to the incorporation of novel culture technologies. Moreover, the combined use of automated bioreactors with the microcarrier technology leads to an efficient expansion and enrichment of the cancer SCs. As a result, these approaches have gained immense traction in this market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cell-expansion-market

Further key findings from the report suggest:

Broad portfolio of automated expansion systems along with improvements in bioreactor design for large-scale bioproduction results in the lucrative growth opportunity for instruments
The microbial cells segment is expected to witness the fastest growth rate owing to the implementation of high-throughput cultivation approaches and techniques that avoid the formation of biofilms
Biopharmaceuticals segment held the largest revenue share in 2019 due to growth in the demand for biosimilars, continuous R&D investments in biomanufacturing, and rise in the number of approvals for biologics
Asia Pacific is anticipated to grow at the maximum CAGR from 2020 to 2027 due to presence of several consortiums that focus on the evolving fields in the biomedical industry
For instance, in November 2019, the Cell & Gene Therapy Asia 2019 held in Japan focused on the evolving field of SCs for their deployment in pharmaceutical discovery and cellular therapies

Next Gen Sequencing Data Analysis Market Worth $1.5 Billion By 2027

The global next gen sequencing data analysis market size is expected to reach USD 1.5 billion by 2027, expanding at a CAGR of 12.9%, according to a new report by Grand View Research, Inc. Next generation sequencing (NGS) has transformed the field of proteomic and genomic research as the technology is highly accurate, offering higher throughput and used for a variety of applications. This includes de novo assembly, transcriptome, whole-genome sequencing, and resequencing for DNA and RNA. Hence, the high adoption of NGS by academic and clinical settings for genomic and proteomic research drives the demand for NGS data analysis tools.

Numerous tools, such as EpiGentek’s Targeted Methyl-Seq platform and Agilent’s HaloPlex capture system, are used to determine DNA methylation profiles across any individual genome. Bisulfite-methylation mapping of whole-genome is currently a feasible technique for targeted sequencing. Besides, expansion of targeted methylation NGS analysis by techniques such as Single Molecule Real-Time Bisulfite Sequencing is driving the market.

Epigentek Group, Inc.; Novogene Co., Ltd.; and CD Genomics are among the few companies that provide services related to targeted bisulfite or methylation sequencing data analysis. Furthermore, key companies are constantly expanding their product line to suffice significant upswing in the demand for these solutions globally. For instance, in July 2020, Pacific Biosciences introduced SMRT Link v9.0 software that is compatible with its Sequel II System.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-ngs-data-analysis-market

Further key findings from the report suggest:

Analytical software is expected to witness significant growth over the forecast period due to the high demand for data management software for managing a large amount of sequenced information
QIAGEN’s CLC Genomics Workbench is one such solution that is a complete toolkit for analyzing transcriptomics, metagenomics, genomics, and epigenomics in one single program
The NGS tertiary data analysis segment held the largest share for workflows in 2019 as it involves the usage of numerous tools
In addition, the tertiary step is an experiment-specific, complex, and time-consuming step of NGS workflow
Availability of software and tools, such as PolyPhen, SIFT, and CIViC, for variant interpretation and annotation, is attributive to the larger share of the segment
The outsourced mode segment has gained immense popularity as it minimizes the requirement of expensive computational infrastructure and complex software tools
SciBerge.Kfm, a German firm, offers outsourced analyzing services to allow its users to interpret NGS information in a fraction of the total price incurred for deep sequencing and DNA library preparation
The wide availability of algorithms and alignment tools for analyzing whole-genome, amplicon, 16S rRNA, methylation, and tumor-normal sequenced data contributes to the dominant revenue share of the short-read segment in 2019
TopHat, Bowtie2, STAR, BWA, Minimap2, and HISAT2 are the commonly used alignment tools for high-throughput short-read sequencing
The academic research end-use segment dominated the market in terms of revenue share in 2019
The rise in the number of skilled professionals, usage of NGS computational tools, and availability of on-site bioinformatics courses and training programs contribute to a larger revenue share
North America dominated the market in 2019 in terms of revenue generation
The launch of large-scale projects to sequence genome, high demand for personalized medicine, constant approval, and favorable reimbursement policies for NGS-based diagnostic tests are among few factors attributive for the region’s larger share
Major market participants have undertaken strategic initiatives to expand the scope of NGS computational tools
For instance, in October 2019, Thermo Fisher signed an agreement with Genialis and integrated its Invitrogen Collibri Stranded RNA Library Prep Kit with Genialis Expressions analysis software to ease the evaluation of RNA sequenced data.

Scaffold Technology Market Worth $1.94 Billion By 2027

The global scaffold technology market size is expected to reach USD 1.94 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.05% from 2020 to 2027. Constant technological advancements in scaffold technology, such as the advent of micropatterned surface microplates and nanofiber-based scaffolds, to facilitate wound repair and soft tissue repair applications boost the revenue generation in the market. A recently developed next-generation injectable microporous scaffold enables organ-on-a-chip technology for the enhancement of in vivo wound healing procedures.

The commercial success of 3D cell culture over the 2D culture system for histological analysis and drug screening purposes has provided lucrative growth avenues for scaffold technology used during 3D cell culturing. This technology minimizes the usage of animal models as it reiterates tissue architectures, thus providing physiologically relevant cellular models for disease investigation.

The broadening horizon of scaffold technology in drug development procedures fuels the market progression. The continual attrition rate in drug development caused due to the inability of monolayer cell culture paves a path for the adoption of scaffold-based cultures that efficiently mimic the disease-causing microenvironment. The rise in demand for novel scaffold-based cultures also reduces the loss of enormous costs involved in the failure of drug development.

The use of biomatrix with incorporated nanoparticles for drug delivery and tissue repair is expected to have a high success rate in the near future. The stem cell therapy, regenerative medicine, and tissue engineering application dominated the market in 2019. The combination of biomaterials and stem cells is an emerging concept useful in cell delivery and tissue construction, which positively impacts the revenue generation in this application. In addition, the presence of supportive organizations, such as the International Society for Stem Cell Research, boosts the demand for 3D scaffolds in this application.

For instance, in May 2019, InVivo Therapeutics introduced a new trial for its neuro-spinal scaffold device, INSPIRE 2.0 study, which widened the scope of a biodegradable device in the treatment of thoracic spinal cord injury. A rise in the number of drug approvals and growth in R&D funding prompt the biotechnology and pharmaceutical companies to widely employ 3D culturing techniques. These techniques act as a robust tool in toxicology and metabolic profiling of drug moieties during the drug development processes.

Asia Pacific is anticipated to expand at the fastest CAGR over the forecast period. Tianjin Municipal Science and Technology Commission and Administrative Commission of the Tianjin Economic-Technological Development Area are China-based funding bodies that boost cell-based research projects in China. For instance, in October 2019, Corning launched Elplasia and Matrigel matrix for organoid culture to support organoid and spheroid culture models, thereby expanding its cell culture portfolio.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/scaffold-technology-market

Further key findings from the report suggest:

By type, nanofiber-based scaffolds are expected to register the fastest growth rate during the forecast period with the expansion of nanoscience and nanotechnology technologies
The stem cell therapy, regenerative medicine, and tissue engineering application segment accounted for the largest revenue share in 2019 and is expected to grow at a lucrative pace in the near future
Stem cell therapy and regenerative medicine are transforming the treatment of neurodegenerative disorders, resulting in the fastest CAGR of the neurology segment
The Asia Pacific is anticipated to witness the fastest growth over the forecast period due to the rise in the number of research grants for cell-based research and tissue engineering projects in this region
Key players such as Merck, Thermo Fisher, Corning, Avacta, Medtronic, Pelobiotech, and Matricel GmbH, have adopted several strategic initiatives to reinforce their market presence

Genomics Market Size Worth $31.1 Billion By 2027

The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period, according to a new report by Grand View Research, Inc. Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.

Increasing pool of market innovators such as 23 and Me,Oxford Nanopore Technologies, and Veritas Genetics that have launched breakthrough genomic technologies in recent years are also contributing toward market development. 23andMe has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has recently received FDA approval for its commercialization.

MinION – a trademark sequencing device of Oxford Nanopore Technologies, is witnessing significant traction owing to its ability to sequence any fragment length of DNA in real time. On the other hand, Veritas Genetics offers an affordable solution for a complete readout of the genomic sequence. Earlier procured only by doctors, these tests can now be taken by anyone curious about their DNA and costs approximately USD 1,000. The company has also begun the commercialization of this technique for newborn’s genomic sequencing applications in China in 2017.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/genomics-market

Further key findings from the report suggest:

The consumables and reagents deliverable segment is expected to register highest growth rate owing to high costs associated with specific essential reagents along with high volume requirement
The computational services deliverable segment is set to expand at a considerable CAGR from 2020 – 2027 owing to the increasing demand for computational sequence alignment and analysis among molecular biologists
Development of predictive biomarkers targeted toward diagnosis and monitoring and substantial investments by biotechnology and pharmaceutical companies have contributed significantly to the revenue generated by the biomarker discovery application segment in 2019
Asia Pacific is a potentially lucrative market for genomics and is anticipated to expand at the highest CAGR of 9.1%
Key players of genomics market include 23andMe; F. Hoffmann-La Roche Ltd.; BGI; Myriad Genetics Inc.; Danaher.; Pacific Biosciences; Illumina; Agilent Technologies; Thermo Fisher Scientific, Inc.; Foundation Medicine; Oxford Nanopore Technologies; and Bio-Rad Laboratories.

Stem Cells Market Size Worth $17.9 Billion By 2027

The global stem cells market size is expected to reach USD 17.9 billion by 2027, expanding at a CAGR of 8.2%, according to a new report by Grand View Research, Inc. Recent advances in tissue engineering strategies hold the potential to draw attention to the treatment of several chronic disorders. Moreover, automation in adult and cord blood processing and storage is expected to drive market growth significantly.

The development of banking facilities and resultant enhancement of stem cell production, storage, and characterization are also expected to enhance the volumetric capabilities of this therapy, globally. This would lead to revenue generation in the global market.

Regenerative medicine and cellular therapies are considered to transform the healthcare industry in a few years. Therefore, key players are focused on developing advanced therapeutics for the treatment of Alzheimer’s disease, Parkinson’s disease, degenerative eye disorders, cancer, and stroke. Most of these therapies are under clinical trials and are expected to be launched soon.

Furthermore, the presence of a strong, diverse clinical pipeline is expected to accelerate revenue generation in the global market. Easy access to data through genomic, proteomic, and EHR databases has encouraged companies to investigate various therapies to aid in the treatment of previously untreatable conditions.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/stem-cells-market

Further key findings from the report suggest:

Adult stem cells (ASCs) segment occupied the largest share of the products in 2019 and is expected to maintain its dominance across the analysis period
Factors such as long term renewal property, low rejection rates, and minimal ethical concerns associated with the utility of ASCs are attributive towards larger market share
The regenerative medicine segment accounted for the largest share of owing to a huge pipeline for regenerative medicine products
The cell acquisition technology segment occupied a major revenue share and is anticipated to witness the fastest CAGR over the forecast period owing to a rise in the number of research projects that require the application of cell harvesting technologies
Allogenic therapy is the most commonly adopted therapy owing to its graft-versus-cancer response in cancer treatment and graft-versus-host response in organ or tissue transplant
These responses allow allogenic stem cells to kill the cancer remaining after drug therapy and to prevent organ rejection and other complications post-surgery
Presence of major companies, extensive government funding, and increasing research have contributed to the largest market share in North America
The Asia Pacific region is expected to grow at a lucrative pace owing to strong product pipelines in regenerative therapies and large patient population
Osiris Therapeutics Inc; BIOTIME, INC.; Celgene Corporation; STEMCELL Technologies Inc.; and Cynata are some of the key players operating in the stem cells market.
The key players are undertaking strategic initiatives to maintain their market share. They are keen to seek investment from other bodies and also collaborate with other pharmaceutical giants. This is set to enhance market growth over the forecast period.

Biological Safety Testing Products and Services Market Worth $6.9 Billion By 2026

The global biological safety testing products and services market size is expected to reach a value of USD 6.9 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 12.3% The market is predominantly driven by increasing production of biologics, which is boosting the need for highly efficient biological safety testing tools. Rising disease burden is expected to be a major factor responsible for high production of biologics, thereby contributing to market growth.

Increasing prevalence of lifestyle-associated chronic diseases such as cancer and diabetes is a key factor contributing to rise in drug development and subsequent commercialization. This is expected to increase the need for scrutinizing & ensuring safety of targeted and specialized therapies, evaluating outcomes, and circumventing probable shortcomings. In addition, pharmaceutical and biotechnology companies are increasingly incorporating biological safety testing products and services to produce highly potent and contamination-free biologics to cater to the large number of people suffering from target diseases. Viral safety testing is proving to be one of the primary concerns of most companies as it is a critical component of chemistry, manufacturing, and control of biologics. This is creating growth opportunities in the market.

Laboratory-based contamination is leading to development and refinement of workstations through incorporation of biological safety products and services. Increasing need to work with tissue cultures, maintain sterility of cell lines, and minimize cross-contamination has increased concerns regarding product integrity. Rising intervention by government healthcare organizations to implement good manufacturing practices and subsequent testing & control at every production stage is expected to widen the scope for growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biological-safety-testing-market

Further key findings from the report suggest:

On the basis of product, reagents and kits accounted for the largest share in 2018 as they are major components that are extensively used in research and clinical laboratories
The instruments segment, on the other hand, is expected to grow at a lucrative CAGR during the forecast period due to rising demand from various clinical and research laboratories
On the basis of application, vaccines & therapeutics segment is expected to grow at a significant CAGR during the forecast period mainly owing to increase in disease outbreaks over the years
Bioburden tests are expected to grow at a lucrative rate during the forecast period owing to their high adoption to determine bioburden limit in a wide range of biologics and medical devices
North America dominated the global biological safety testing products and services market in 2018 owing to high R&D investments in biotechnology and huge chronic disease burden
Asia Pacific is expected to grow at an exponential CAGR during the forecast period owing to increase in healthcare spending
Some of the key players are Charles River Laboratories International, Inc.; Lonza Group AG; MilliporeSigma; SGS SA; Sartorius Stedim BioOutsource Limited; and BSL Bioservice Scientific Laboratories GmbH.

Human Embryonic Stem Cells Market Size Worth $1.06 Billion By 2025

The global human embryonic stem cells market size is anticipated to reach USD 1.06 billion by 2025, according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.

Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.

In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.

Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.

However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/human-embryonic-stem-cell-market

Further Key Findings from the Report Suggest:

hESC derivation provides a unique opportunity for early human development studies
It is believed to hold a substantial potential for regenerative medicine and biopharma
Differentiated derivatives of these cells are applicable for screening assays in development of novel pharmaceutical moieties
Screening for mutagenic as well as toxic compounds can also be carried out using such derivatives
Presence of lack of suitable donor organs and tissues for regenerative medicine is expected to increase the demand thus influencing growth
Stem cell research is anticipated to exhibit fastest growth amongst the other applications
However, presence of controversies pertaining to their use as a consequence of ethical considerations is responsible for steady growth
Europe accounts for considerable share of the market, following North America
As per a recent survey carried out by Swiss government, citizens there are more willing to accept embryonic stem cell research than politicians
Asia Pacific is anticipated to drive market with fastest YoY growth
Rising awareness amongst the population and physicians with respect to associated therapies is anticipated to propel progress
Key players contributing in this market are CellGenix GmbH, International Stem Cell Corporation, Thermo Fisher Scientific, Inc.; Kite Pharma, PromoCell GmbH, and Lonza
Presence of clinical trial pipeline for embryonic stem cell derived therapy for targeting different diseases is expected to fuel growth.
The diseases targeted include macular degeneration, Parkinson’s disease, type I diabetes mellitus, and spinal cord injury.

Cancer Biomarkers Market Worth $33.7 Billion By 2025

The global cancer biomarkers market size is expected to reach a value of USD 33.7 billion by 2025, at a CAGR of 14.3% based on a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.

In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.

People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/cancer-biomarker-market

Further Key findings from the study suggest:

Breast cancer was the largest segment by revenue share in 2016 owing to high prevalence of this type of cancer
Lung cancer is estimated to be the fastest-growing type due to increasing research activities toward development of novel lung cancer biomarkers
Genetic biomarkers, being the highest used and easily detectable held the majority share of cancer biomarker market by biomolecule in 2016
However, epigenetic biomarkers are anticipated to witness lucrative growth due to increasing focus on finding the role of epigenetic modifications in cancer development
Cancer biomarkers are majorly used for diagnostic purpose owing to their high specificity
The personalized medicine segment is estimated to witness fastest CAGR of 15.0% over the forecast period
North America dominated in terms of revenue share in 2016 due to established R&D infrastructure and high acceptance of biomarker-based cancer testing in this region
Asia Pacific is anticipated to grow at a substantial growth rate till 2025 with CAGR of over 16.7%
Some of the major companies in the cancer biomarkers market are Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company

pH Meters Market Size To Reach $1.95 Billion By 2022

Global pH meters market is expected to reach nearly USD 1,951.2 million by 2022 according to a new report by Grand View Research Inc. Key factors attributing to the market growth are introduction of technologically advanced portable and bench top pH meters, growing concerns to monitor environmental pollution and the need to regulate pH levels in various consumable products.

Increasing demand for quality control and routine testing of soil, water, food, beverage, and dairy products is driving the use of new generation pH meters with multi-parameter analysis. The new devices are improving the efficiency, accuracy, ease of usage, and cost-effectiveness, which are expected to serve as high-impact rendering drivers over the forecast period.

Increasing awareness regarding the need to regulate waste water pH in industries such as chemicals, pharmaceuticals, food processing, and other end use sectors is a key factor boosting the usage rates. pH neutralization of the waste water discharged from these industries is critical to prevent corrosion of sewage pipes and prevent leakage of harmful substances in to the land and other water bodies.

Furthermore, growing awareness about soil pH and its impact on plant nutrient absorption is a key factor boosting the soil pH analysis. Maintaining the appropriate ratio of nitrogen, phosphorous, and potassium (N-P-K) in the soil plays an important role in improving the product yield, quality, and also improves resistance to various diseases. The shift towards scientific agricultural practices and growing demand for organic farming, soil testing, irrigational water testing, are some the key factors expected to positively reinforce market growth over the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/ph-meter-market

Further key findings from the study suggest:

In 2014, bench top pH meters were the largest segment accounting for nearly 57% of the market. Bench top pH meters are widely used in different industries, research labs and commercial testing centers owing to their advanced features, ease of operation, durability of the sensors, and accuracy.
Portable pH meters are expected to be the fastest growing segment over the forecast period. Low cost of these devices, high accuracy and ability to monitor pH of samples at any location are major factors expected to boost the usage rates in the next seven years.
In 2014, Europe dominated the overall pH meters market with nearly 34% share. Some key factors attributed to the high share are presence of stringent environmental regulations, awareness about scientific agricultural, food and beverage manufacturing practices.
However, Asia Pacific is expected to the fastest growing with a CAGR of 7.9% over the forecast period. The shift from traditional agricultural practices to scientific and organic farming, increasing emphasis on managing waste water discharge, and increasing demand from academic, food processing, beverages and other end use industries are key factors expected to reinforce the market growth over the forecast period.
The market is witnessing high competition due to the presence of a large number of small and medium scale manufacturers catering to regional demand. Key market players include Thermo Fisher Scientific, Danaher Corporation, Mettler Toledo, Metrohm USA, Hanna Instruments, Agilent Technologies, and Perkin Elmer.

Research Antibodies Market Worth $5.6 Billion By 2027

The global research antibodies market size is expected to reach USD 5.6 billion by 2027, exhibiting a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. Major market drivers include rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, growing interest in the study of neurobiology and stem cell, availability of technologically advanced products, and strategic collaborations among various market players and academic research organizations.

Designer antibodies are also anticipated to attract the attention of various academic organizations for their use in the R&D of novel products. For instance, in April 2019, scientists from ALS Canada Research Program developed a set of antibodies that can help in the detection of misfolded TDP-43 in various lab experiments that utilize post-mortem brain tissues. Rising usage of research antibodies for the development of novel diagnostic therapies is thus anticipated to fuel market growth in the near future.

Increase in the usage of research antibodies to develop treatment options for various diseases is also expected to boost market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid in the understanding of various aspects of virus pathogenesis, entailing further research on antiviral therapies. Growing government funds and initiatives for R&D is anticipated to fuel the Asia Pacific market during the forecast period. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, rise in funds invested by pharmaceutical and biotechnology companies to enhance the study of proteomics and genomics is expected to drive the market. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. Rise in the number of major market players investing in advanced technologies and collaborating with other market players is also anticipated to positively impact market potential in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and to discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies.

North America dominated the research antibodies market in owing to increasing focus on R&D in the fields of biomedicine, stem cell, and cancer. Rising prevalence of chronic diseases such as cardiovascular and blood diseases is also expected to fuel market growth.

Launch of novel antibody structures for diagnosis of various diseases is also a major factor expected to boost the market. For instance, in August 2018, BioGenex launched a range of new antibodies for its use in cancer immunohistochemistry. The company’s immunohistochemistry solution offers about 400 reagents, primary antibodies, consumables, and ancillaries. Key players in the market include Abcam Plc; Bio-Rad Laboratories Inc.; PerkinElmer, Inc.; Agilent Technologies; Roche; Cell Signalling Technology, Inc.; Thermo Fisher Scientific; Lonza Group; and BD.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/research-antibodies-market

Further key findings from the study suggest:

By product, primary antibodies held the dominant share in 2019 in terms of revenue owing to greater specificity, therefore leading to increased adoption in R&D activities
Based on type, monoclonal antibodies captured a substantial market share in 2019 as they offer higher sensitivity for detection of antigens and also showcase efficient staining properties for various applications
The Western blotting technology segment has witnessed exponential growth owing to increasing prevalence of diseases with limited treatment options and rise in R&D activities conducted by pharmaceutical and biotechnology companies and academic institutes
Based on end use, pharmaceutical and biotechnology companies were dominant in terms of revenue in 2019 owing to increased adoption of research antibodies in drug development and discovery
North America accounted for a substantial share of the research antibodies market in 2019, which is attributable to high presence of many biotechnologies as well as biopharmaceutical manufacturers, research academies, and laboratories.